442 related articles for article (PubMed ID: 15919798)
1. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.
Herold KC; Gitelman SE; Masharani U; Hagopian W; Bisikirska B; Donaldson D; Rother K; Diamond B; Harlan DM; Bluestone JA
Diabetes; 2005 Jun; 54(6):1763-9. PubMed ID: 15919798
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.
Herold KC; Hagopian W; Auger JA; Poumian-Ruiz E; Taylor L; Donaldson D; Gitelman SE; Harlan DM; Xu D; Zivin RA; Bluestone JA
N Engl J Med; 2002 May; 346(22):1692-8. PubMed ID: 12037148
[TBL] [Abstract][Full Text] [Related]
3. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.
Sherry N; Hagopian W; Ludvigsson J; Jain SM; Wahlen J; Ferry RJ; Bode B; Aronoff S; Holland C; Carlin D; King KL; Wilder RL; Pillemer S; Bonvini E; Johnson S; Stein KE; Koenig S; Herold KC; Daifotis AG;
Lancet; 2011 Aug; 378(9790):487-97. PubMed ID: 21719095
[TBL] [Abstract][Full Text] [Related]
4. Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis.
Perdigoto AL; Preston-Hurlburt P; Clark P; Long SA; Linsley PS; Harris KM; Gitelman SE; Greenbaum CJ; Gottlieb PA; Hagopian W; Woodwyk A; Dziura J; Herold KC;
Diabetologia; 2019 Apr; 62(4):655-664. PubMed ID: 30569273
[TBL] [Abstract][Full Text] [Related]
5. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).
Herold KC; Burton JB; Francois F; Poumian-Ruiz E; Glandt M; Bluestone JA
J Clin Invest; 2003 Feb; 111(3):409-18. PubMed ID: 12569167
[TBL] [Abstract][Full Text] [Related]
6. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.
Herold KC; Gitelman S; Greenbaum C; Puck J; Hagopian W; Gottlieb P; Sayre P; Bianchine P; Wong E; Seyfert-Margolis V; Bourcier K; Bluestone JA;
Clin Immunol; 2009 Aug; 132(2):166-73. PubMed ID: 19443276
[TBL] [Abstract][Full Text] [Related]
7. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.
Aronson R; Gottlieb PA; Christiansen JS; Donner TW; Bosi E; Bode BW; Pozzilli P;
Diabetes Care; 2014 Oct; 37(10):2746-54. PubMed ID: 25011949
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD3 antibodies OKT3 and hOKT3gamma1(Ala-Ala) induce proliferation of T cells but impair expansion of alloreactive T cells; aspecifc T cell proliferation induced by anti-CD3 antibodies correlates with impaired expansion of alloreactive T cells.
Popma SH; Griswold DE; Li L
Int Immunopharmacol; 2005 Jan; 5(1):155-62. PubMed ID: 15589476
[TBL] [Abstract][Full Text] [Related]
9. Teplizumab for treatment of type 1 diabetes mellitus.
Skelley JW; Elmore LK; Kyle JA
Ann Pharmacother; 2012 Oct; 46(10):1405-12. PubMed ID: 22968521
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD3 antibody MacroGenics Inc.
Brown WM
Curr Opin Investig Drugs; 2006 Apr; 7(4):381-8. PubMed ID: 16625825
[TBL] [Abstract][Full Text] [Related]
11. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
Keymeulen B; Vandemeulebroucke E; Ziegler AG; Mathieu C; Kaufman L; Hale G; Gorus F; Goldman M; Walter M; Candon S; Schandene L; Crenier L; De Block C; Seigneurin JM; De Pauw P; Pierard D; Weets I; Rebello P; Bird P; Berrie E; Frewin M; Waldmann H; Bach JF; Pipeleers D; Chatenoud L
N Engl J Med; 2005 Jun; 352(25):2598-608. PubMed ID: 15972866
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD3 antibodies for type 1 diabetes: beyond expectations.
Bach JF
Lancet; 2011 Aug; 378(9790):459-60. PubMed ID: 21719098
[No Abstract] [Full Text] [Related]
13. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial.
Herold KC; Gitelman SE; Willi SM; Gottlieb PA; Waldron-Lynch F; Devine L; Sherr J; Rosenthal SM; Adi S; Jalaludin MY; Michels AW; Dziura J; Bluestone JA
Diabetologia; 2013 Feb; 56(2):391-400. PubMed ID: 23086558
[TBL] [Abstract][Full Text] [Related]
14. Generation and function of human regulatory CD8+ T cells induced by a humanized OKT3 monoclonal antibody hOKT3gamma1 (Ala-Ala).
Ablamunits V; Herold KC
Hum Immunol; 2008 Nov; 69(11):732-6. PubMed ID: 18817833
[TBL] [Abstract][Full Text] [Related]
15. Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes.
Long SA; Thorpe J; Herold KC; Ehlers M; Sanda S; Lim N; Linsley PS; Nepom GT; Harris KM
Cell Immunol; 2017 Sep; 319():3-9. PubMed ID: 28844471
[TBL] [Abstract][Full Text] [Related]
16. Insulin secretion in type 1 diabetes.
Steele C; Hagopian WA; Gitelman S; Masharani U; Cavaghan M; Rother KI; Donaldson D; Harlan DM; Bluestone J; Herold KC
Diabetes; 2004 Feb; 53(2):426-33. PubMed ID: 14747294
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD3 clinical trials in type 1 diabetes mellitus.
Daifotis AG; Koenig S; Chatenoud L; Herold KC
Clin Immunol; 2013 Dec; 149(3):268-78. PubMed ID: 23726024
[TBL] [Abstract][Full Text] [Related]
18. Preexisting insulin autoantibodies predict efficacy of otelixizumab in preserving residual β-cell function in recent-onset type 1 diabetes.
Demeester S; Keymeulen B; Kaufman L; Van Dalem A; Balti EV; Van de Velde U; Goubert P; Verhaeghen K; Davidson HW; Wenzlau JM; Weets I; Pipeleers DG; Gorus FK
Diabetes Care; 2015 Apr; 38(4):644-51. PubMed ID: 25583753
[TBL] [Abstract][Full Text] [Related]
19. Clinical and metabolic characteristics of patients with latent autoimmune diabetes in adults (LADA): absence of rapid beta-cell loss in patients with tight metabolic control.
Chaillous L; Bouhanick B; Kerlan V; Mathieu E; Lecomte P; Ducluzeau PH; Delamaire M; Sonnet E; Maugendre D; Maréchaud R; Rohmer V; Saï P; Charbonnel B
Diabetes Metab; 2010 Feb; 36(1):64-70. PubMed ID: 20060765
[TBL] [Abstract][Full Text] [Related]
20. Use of anti-CD3 monoclonal antibody to induce immune regulation in type 1 diabetes.
Bisikirska BC; Herold KC
Ann N Y Acad Sci; 2004 Dec; 1037():1-9. PubMed ID: 15699486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
